Skip to Content
scroll

Neuren Pharmaceuticals Ltd (NEU)

ASX.NEU $5.44

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

ASX.NEU $5.44

20 MINUTE DELAYED

TODAY

-2.86 %

1 YEAR RETURN

0.00%

VOLUME

87,304

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

1.63

5.99

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

5.44

Change

-0.16 (-2.86)

Bid / Ask

5.39 - 5.51

Volume

87,304

Volume (3mths avg)

0

Turnover

474,926

Open

5.59

Day Range

5.38 - 5.59

VWAP

5.44

Prev Close

5.60

Last Trade

17/08 4:10pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

0

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

Dividend Pay Date

29 MAR 2006

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

Yield %

0.00

Market Cap

0.00

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
image description

Business Summary

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company that is engaged in developing drugs for neurological disorders. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The Company has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The Company is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.
image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top